Loading company
Kiora Pharmaceuticals Inc.
KPRX · Nasdaq · ·
Next earnings: November 6, 2026
$2.67+0.8%Sep 29 close
- 1M
- +1.9%
- 6M
- +41.3%
- 1Y
- -4.0%
- 5Y
- -99.6%
KPRX · Nasdaq · ·
Next earnings: November 6, 2026
$2.67+0.8%Sep 29 close
Kiora Pharmaceuticals Inc. is scheduled to report next on November 6, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending December 31, 2025, against the same quarter a year earlier.
| Measure | 3 months toDec 31, 2025 | 3 months toDec 31, 2024 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | — |
| Profit | -$2.1M | -$2.2M | +3.41% |
| Profit per share | -$0.34 | -$0.54 | +37.04% |
| Free Cash Flow | -$1.9M | -$3.8M | +50.06% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“Patient demand for ABACUS-2 remains high as we have begun to enroll the higher 100 µg dose cohort,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Kiora Pharmaceuticals is a clinical-stage biotechnology company developing therapies for retinal diseases. The Company uses small molecules to target biological pathways involved in inherited retinal degeneration, retinal inflammation and vision loss. KIO-301 is a molecular photoswitch being developed initially to restore vision in patients with late-stage retinitis pigmentosa, regardless of the genetic mutation responsible for the disease. The program may also have potential applications in other retinal degenerative conditions. Kiora has granted Théa Open Innovation an exclusive license to develop and commercialize KIO-301 outside Asia. KIO-104 is a non-steroidal, small-molecule inhibitor of DHODH being developed for retinal inflammation and associated macular edema. It is designed for local ocular administration to regulate immune-cell activity within the eye while limiting systemic exposure. In addition to news releases and SEC filings, Kiora expects to post information on its website, www.kiorapharma.com , and its social media accounts that could be relevant to investors. Investors are encouraged to follow Kiora on X and LinkedIn and to visit the Company’s website or subscribe to email alerts.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Kiora Pharmaceuticals Inc.’s Item 2.02 8-K filed August 7, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Kiora Pharmaceuticals Inc. has no earnings call transcript available.